The widespread acceptance of sulfanilamide and other sulfanilyl compounds as effective agents in the treatment of gonococcic infections has modified the value of all preexisting types of therapy. The rapidity with which many cases yield to intelligent and controlled administration of these drugs has obviated the necessity for the use of accessory therapeutic agents in such cases. The brilliance of such results has been dimmed somewhat by the development of several circumstances which will prevent the ultimate eradication of the disease: the asymptomatic carrier,1the development of chemotherapy-fast strains of the gonococcus2and the occurrence of relapse after apparent cure.3Even in instances in which the patient has received what was thought to be adequate treatment, sulfanilamide may fail completely to eradicate the infection. Indeed, in a survey by Dees and Young4of 2,727 well analyzed cases collected from the literature only 1,848 (68 per cent)